Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression
A Short Term Double Blind Randomised Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression
Sponsor: Hillerod Hospital, Denmark
Terminated
lack of participants fulfilling inclusion criteria
Listed as NCT00159146, this NA trial focuses on Major Depression and remains terminated or withdrawn. Sponsored by Hillerod Hospital, Denmark, it has been updated 7 times since 2002, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Study Description(click to expand)Antidepressant therapy has a delayed onset of action of 4-6 weeks. Pindolol has in some studies shown an accelerating effect. In this study we investigate the effect of 20 mg of pindolol retarded formulation in combination with Venlafaxine compared to placebo Pindolol and Venlafaxine for a duration of 19 days.
Effect is measured by the Hamilton Depression rating Scale and the Preskorn Scale (self-rating).
Antidepressant therapy has a delayed onset of action of 4-6 weeks. Pindolol has in some studies shown an accelerating effect. In this study we investigate the effect of 20 mg of pindolol retarded formulation in combination with Venlafaxine compared to placebo Pindolol and Venlafaxine for a duration of 19 days.
Effect is measured by the Hamilton Depression rating Scale and the Preskorn Scale (self-rating).
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Terminated NA
-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Jan 2017 — Jun 2018 [monthly]
Terminated NA
First recorded
Aug 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hillerod Hospital, Denmark
- Tvergaards Foundation
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .